Testing methods for choosing drug candidates
Synovo GmbH is a pharmaceutical research company that offers services in the fields of synthetic chemistry, pharmacology, cell engineering and peptide modification.
The company’s focus lies in providing various testing methods and models – ideally using human cells, proteins or systems – for the selection of drug candidates with improved properties in terms of absorption, distribution, metabolism and elimination (ADME or DMPK). On behalf of customers from the pharmaceutical industry, Synovo is involved in projects investigating anti-inflammatory and immuno-suppressive drug optimisation and the improvement of existing technologies used for the development of new drugs from proteins and nucleic acids. This work is carried out in collaboration with public-sector laboratories.
+49 7071 964325
Dr. Michael Burnet
Using your own head and hands to create something new and better
BioGrafie – Dr Michael Burnet, Managing Director Synovo GmbH (Stuttgart/Tübingen) – Dr Michael Burnet is an entrepreneur, managing director, researcher and inventor who has…
Synovo announces entry into development of its Covid-19 viral pneumonia therapy candidate.
Synovo GmbH announced that it will accelerate development of SYD015, a compound designed to treat acute viral and bacterial pneumonia and acute respiratory distress syndrome (ARDS…